BridgeBio Pharma, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
BBIO$78.67+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenues: | ||
| Net product revenue | $180,596 | $36,739 |
| License and services revenue | 4,419 | 79,690 |
| Royalty revenue | 9,500 | 204 |
| Total revenues, net | 194,515 | 116,633 |
| Operating costs and expenses: | ||
| Cost of revenues: | ||
| Cost of goods sold | 7,732 | 2,034 |
| Cost of license, services, and royalty revenue | 2,207 | 605 |
| Total cost of revenues | 9,939 | 2,639 |
| Research and development | 126,636 | 111,431 |
| Selling, general and administrative | 163,896 | 106,365 |
| Restructuring, impairment, and related charges | — | 570 |
| Total operating costs and expenses | 300,471 | 221,005 |
| Loss from operations | (105,956) | (104,372) |
| Other income (expense), net: | ||
| Interest income | 6,246 | 5,385 |
| Interest expense | (12,942) | (18,121) |
| Noncash interest expense on deferred royalty obligations (1) | (39,873) | (24,020) |
| Loss on extinguishment of debt | — | (21,155) |
| Net loss from equity method investments | (18,283) | (15,556) |
| Other income, net | 4,253 | 8,231 |
| Total other expense, net | (60,599) | (65,236) |
| Net loss | (166,555) | (169,608) |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 2,512 | 2,186 |
| Net loss attributable to common stockholders of BridgeBio | $(164,043) | $(167,422) |
| Net loss per share attributable to common stockholders of BridgeBio, basic and diluted | $(0.84) | $(0.88) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic and diluted | 194,789,897 | 190,145,253 |
(1)Including a related party amount of $(5,361) for the three months ended March 31, 2026 (as described in Note 9).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.